Sox4, EMT programs, and the metastatic progression of breast cancers: Mastering the masters of EMT

Breast Cancer Research

Volumn 15, Issue 4, 2013, Pages

  Parvani, Jenny G ^a   Schiemann, William P ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; NOTCH RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX4; TRANSFORMING GROWTH FACTOR BETA; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR SOX;

ARTICLE; BREAST EPITHELIUM; BREAST METASTASIS; CANCER GROWTH; CELL FATE; CELL STRUCTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE SEVERITY; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; MECHANOTRANSDUCTION; METASTASIS FREE SURVIVAL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANIMAL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; PHYSIOLOGY;

ANIMALS; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; POLYCOMB REPRESSIVE COMPLEX 2; SOXC TRANSCRIPTION FACTORS;

EID: 84887559834     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3466     Document Type: Article

References (19)

1. Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 1982, 95:333-339. 10.1083/jcb.95.1.333, 2112361, 7142291.
2. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development 2012, 139:3471-3486. 10.1242/dev.071209, 22949611.
3. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15:117-134. 10.1007/s10911-010-9178-9, 2886089, 20490631.
4. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010, 15:169-190. 10.1007/s10911-010-9181-1, 3721368, 20467795.
5. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939. 10.1016/j.cell.2004.06.006, 15210113.
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
7. Parvani JG, Taylor MA, Schiemann WP. Noncanonical TGF-beta signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2011, 16:127-146. 10.1007/s10911-011-9207-3, 3723114, 21448580.
8. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428. 10.1172/JCI39104, 2689101, 19487818.
9. Gunasinghe NP, Wells A, Thompson EW, Hugo HJ. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 2012, 31:469-478. 10.1007/s10555-012-9377-5, 22729277.
10. Kiefer JC. Back to basics: Sox genes. Dev Dyn 2007, 236:2356-2366. 10.1002/dvdy.21218, 17584862.
11. Jafarnejad SM, Ardekani GS, Ghaffari M, Li G. Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. Cell Mol Life Sci 2013, 70:2677-2696. 10.1007/s00018-012-1187-y, 23080209.
12. Vervoort SJ, Lourenco AR, van Boxtel R, Coffer PJ. SOX4 mediates TGF-beta-induced expression of mesenchymal markers during mammary cell epithelial to mesenchymal transition. PLoS One 2013, 8:e53238. 10.1371/journal.pone.0053238, 3536747, 23301048.
13. Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, Feng J, Zhang Y, Gao H, Liu DX, Lu J, Huang B. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res 2012, 72:4597-4608. 10.1158/0008-5472.CAN-12-1045, 22787120.
14. Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schubeler D, van Nimwegen E, Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 2013, 23:768-783. 10.1016/j.ccr.2013.04.020, 23764001.
15. Ansieau S, Courtois-Cox S, Morel AP, Puisieux A. Failsafe program escape and EMT: a deleterious partnership. Semin Cancer Biol 2011, 21:392-396.
16. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. 10.1038/nature11412, 3465532, 23000897, Cancer Genome Atlas Network.
17. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767. 10.1172/JCI45014, 3127435, 21633166.
18. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010, 7:683-692. 10.1038/nrclinonc.2010.154, 20877296.
19. Crea F, Paolicchi E, Marquez VE, Danesi R. Polycomb genes and cancer: time for clinical application?. Crit Rev Oncol Hematol 2012, 83:184-193. 10.1016/j.critrevonc.2011.10.007, 22112692.